TerminatedPhase 2NCT01442714

Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDS

Studying Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Stanford University
Principal Investigator
Bruno Carneiro de Medeiros, MD
Stanford University
Intervention
Azacitidine(drug)
Enrollment
33 enrolled
Eligibility
60 years · All sexes
Timeline
20112014

Study locations (1)

Collaborators

Celgene Corporation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01442714 on ClinicalTrials.gov

Other trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

Additional recruiting or active studies for the same condition.

See all trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent

← Back to all trials